Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643456 | 0.86 | AKR1C3 (0.46) | NPC1RAB9AHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL2451836 | 0.85 | TSHR (0.50) | HPGDERCC5FEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12483224 | 0.85 | ESR1 (0.47) | NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL6002891 | 0.81 | KCNK3 (0.53) | NPC1RAB9AKCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL4711341 | 0.79 | NPC1 (0.43) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL336772 | 0.78 | NPC1 (0.46) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL430940 | 0.78 | NPC1 (0.46) | NPC1RAB9AHPGDKCNK3KCNK9 | |
| SCHEMBL2723991 | 0.76 | TSHR (0.41) | HPGDALDH1A1TSHRACHE | |
| SCHEMBL38015 | 0.76 | CES1 (0.52) | HPGDSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL20659157 | 0.74 | SMN1; SMN2 (0.50) | NPC1RAB9AHPGDERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2246916-A2 | Amine dye for a dye sensitized solar cell | Konica Minolta Business Technologies, Inc. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-2225251-A1 | TRANSITION METAL COMPLEXES, CATALYSTS COMPOSITION CONTAINING THE SAME, AND PROCESS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND ALPHA-OLEFINS USING THE SAME | SK Energy Co., Ltd. (KR) | 2010-09-08 | — | — | EP | disclosed |
| EP-2091945-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009084805-A1 | TRANSITION METAL COMPLEXES, CATALYSTS COMPOSITION CONTAINING THE SAME, AND PROCESS FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND ALPHA-OLEFINS USING THE SAME | SK ENERGY CO., LTD. (KR) | 2009-07-09 | — | — | WO | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | NPC1 2022/4885RAB9A 2143/4885HPGD 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.